17687-24-0

Basic information

• Product Name: 5-NITROOROTIC ACID
• Synonyms: 5-NITROOROTIC ACID;2,4-DIHYDROXY-5-NITRO-6-CARBOXYPYRIMIDINE;1,2,3,6-TETRAHYDRO-5-NITRO-2,6-DIOXO-4-PYRIMIDINECARBOXYLIC ACID;NITRO-OROTIC ACID;1,2,3,6-tetrahydro-5-nitro-2,6-dioxopyrimidine-4-carboxylic acid;1,2,3,6-Tetrahydro-5-nitro-2,6-dioxo-4-pyrimidinecarboxylicacid;5-nitro-2,4-dioxo-1H-pyriMidine-6-carboxylic acid;2,6-Dihydroxy-5-nitro-pyrimidine-4-carboxylic acid
• CAS NO: 17687-24-0
• Molecular Formula: C₅H₃N₃O₆
• Molecular Weight: 201.09
• EINECS: 241-671-1
• Mol File: 17687-24-0.mol
• Article Data: 10

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.95g/cm³
• Refractive Index: 1.656
• Storage Temp.: 2-8°C
• PKA: -0.10±0.20(Predicted)
• CAS DataBase Reference: 5-NITROOROTIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-NITROOROTIC ACID(17687-24-0)
• EPA Substance Registry System: 5-NITROOROTIC ACID(17687-24-0)

Safety Data

• Hazardous Substances Data: 17687-24-0(Hazardous Substances Data)

Usage

Description

5-Nitroorotic acid (CAS# 17687-24-0) is an organic compound that has been identified for its potential applications in various fields, particularly in the development of antiparasitic drugs. It is characterized by its unique chemical structure, which allows it to interact with specific biological targets and contribute to the design and development of novel therapeutic agents.

Uses

Used in Pharmaceutical Industry:
5-Nitroorotic acid is used as a molecular docking agent for predicting the selectivity of different classes of antiparasitic plant-derived terpenoids towards Leishmania protein targets. This application is crucial in fragment or structure-based antileishmanial drug design and development, as it helps researchers understand the interactions between potential drug candidates and their target proteins, ultimately leading to the creation of more effective and selective treatments for Leishmania infections.

InChI:InChI=1/C5H3N3O6/c9-3-2(8(13)14)1(4(10)11)6-5(12)7-3/h(H,10,11)(H2,6,7,9,12)

Upstream product

• 626-48-2 6-Methyluracil 
• 56-04-2 6-methyl-2-thiouracil 
• 65-86-1 orotic acid 
• 65-86-1 2,4-dihydroxypyrimidine-6-carboxylic acid 
• 154-85-8 orotic acid sodium salt 
• 5435-44-9 (E)-3-Ureido-but-2-enoic acid ethyl ester 
• 16632-21-6 5-nitro-6-methyluracil 

Downstream Products

• 611-08-5 5-nitrobarbituric acid 
• 52047-16-2 ethyl 5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate 
• 52047-13-9 methyl 2,6-dichloro-5-nitro-4-pyrimidinecarboxylate 
• 6311-73-5 methyl 2,6-dihydroxy-5-nitropyrimidine-4-carboxylate 
• 189747-29-3 5-amino-2-chloropyrimidine-4-carboxamide 
• 189747-34-0 2,8-dichloropyrimido(5,4-d)pyrimidine 

Relevant articles and documents

NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds as inhibitors of receptor tyrosine kinases, in particular oncogenic mutants of ErbB-receptors e.g. in the treatment of cancer.

Method for synthesizing 2-chloro-5-amino-6-pyrimidine ethyl formate

The invention discloses a method for synthesizing 2-chloro-5-amino-6-pyrimidine ethyl formate. The method comprises the following steps: firstly, enabling fuming nitric acid, concentrated sulfuric acid and orotic acid to react so as to obtain nitroorotic acid; further mixing the obtained nitroorotic acid with ethanol, and adding dropwise the concentrated sulfuric acid at room temperature so as toobtain nitroorotic acid ethyl ester; enabling the nitroorotic acid ethyl ester to react with phosphorus oxychloride and an organic alkali so as to obtain 2,4-dichloro-5-nitro-6-pyrimidine ethyl formate; and finally mixing the 2,4-dichloro-5-nitro-6-pyrimidine ethyl formate with palladium carbon and magnesium oxide, putting the mixture into tetrahydrofuran, and performing a reaction, so as to obtain a final product. By adopting the method, the orotic acid in the market is adopted as a raw material, and the 2-chloro-5-amino-6-pyrimidine ethyl formate is prepared through reactions of nitration, esterification, chlorination and reduction. The method is convenient in process operation, simple in operation, gentle in reaction and small in pollution, in addition, the prepared pyrimidine is high in yield and purity and small in environment pollution, and the prepared 2-chloro-5-amino-6-pyrimidine ethyl formate prepared by using the method can be applied to large-scale production.

Production method of dipyridamole bulk drug

The invention provides a production method of a bulk drug of dipyridamole, which relates to the field of the synthesis of chemical bulk drugs. The production method comprises the following steps: protecting carbonyl of urea, performing condensation reaction with 2,3-diaminosuccinic acid, performing chlorination for hydroxyl of a condensation reactant, replacing chlorine with piperidine, hydrolyzing an obtained product, obtaining a compound containing two carbonyls, separating the product, enabling the separated product to have condensation reaction with diethanol amine, obtaining dipyridamole,and refining to obtain a finished product. By adopting the production method, the synthetic procedure of the dipyridamole is simplified, the conversion rate of raw materials can be greatly increased,and the production cost is decreased.